Mesa, Arizona August 24th, 2022 – Fusion Orthopedics, LLC (“Fusion”) (www.fusionorthopedics.com) is a medical device company established in 2014 and known for numerous innovative technologies in the foot and ankle orthopedic market.

LapiLock 4D Advanced Bunion Surgery was previously in limited market release (“LMR”). In March of 2022 LapiLock 4D Advanced Bunion Surgery was thrust into the national spotlight by Treace Medical Concepts, Inc. (“Treace”). Treace’s Lapiplasty is a direct competitor of Fusion’s LapiLock. Fusion Orthopedics stands by its disruptive bunion surgery technology.

Today, Fusion Orthopedics, LLC announces the full commercial release of their LapiLock 4D Advanced Bunion Surgery. The first phase of nationally available inventory increases Fusion’s LapiLock bunion surgery capacity to capture potentially thousands of bunion surgery cases in the third quarter of 2022. Fusion Orthopedics aims to be the bunion surgery category leader in revenue, clinical outcomes, and surgeon preference supported by fiercely loyal distribution partners.

Fusion believes the LapiLock 4D Advanced Bunion Surgery is disruptive for many reasons:

  1. Surgeon’s choice of over 13 options for fixation;

  2. Counter pressure will never break a patient’s second metatarsal;

  3. No c-clamp eliminating metatarsal “spring-back” risk;

  4. Minimal bone resection to better maintain first metatarsal length;

  5. Adjustability of dorsal flex or plantar flex of the first metatarsal;

  6. Fulcrum-less surgical technique; 

  7. Single jig for all steps to eliminate risk/loss of correction;

  8. Faster operating room time intended;

  9. Flexibility in pricing to address unmet market demand

For more information visit lapilock.com

Interested in LapiLock 4D Advanced Bunion Surgery?

Media Contact:

Samuel Rocereta, Esq
General Counsel
(480) 409-7169
sam@fusionorthopedics.com